Caricamento...
Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells
Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing...
Salvato in:
| Pubblicato in: | Adv Pharm Bull |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Tabriz University of Medical Sciences
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6983993/ https://ncbi.nlm.nih.gov/pubmed/32002360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15171/apb.2020.005 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|